BackAvid Bioservices Overview

Avid Bioservices Total Current Liabilities

Track Avid Bioservices's total current liabilities ($74M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$74.16M
3.61% YoYΔ $-2.78M vs prior year quarter

Peer average

Loading

Avid Bioservices Total Current Liabilities History

Loading

Avid Bioservices vs. peers: Total Current Liabilities Comparison

Loading

Avid Bioservices Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Avid Bioservices (CDMO) FAQ

Avid Bioservices's total current liabilities stands at $74M as of October 2024. That compares with $77M in the prior-year period — down 3.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Avid Bioservices reported $74M in total current liabilities versus $77M a year earlier — a 3.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $77M in the prior-year period — down 3.6% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Avid Bioservices's total current liabilities evolved across reporting periods, while the comparison chart places CDMO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Avid Bioservices's reading of $74M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.